Swift, Imogen J.
Sjödin, Simon
Gobom, Johan
Brinkmalm, Ann
Blennow, Kaj
Zetterberg, Henrik
Rohrer, Jonathan D.
Sogorb-Esteve, Aitana http://orcid.org/0000-0002-7869-8192
Article History
Received: 15 August 2023
Revised: 11 October 2023
Accepted: 12 October 2023
First Online: 2 November 2023
Declarations
:
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JDR has served on medical advisory boards and consultancy for Alector, Arkuda Therapeutics, Wave Life Sciences, and Prevail Therapeutics. Consultancy for UCB, AC Immune, Astex Pharmaceuticals, Biogen, Takeda and Eisai. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. ASE, SS, JG, AB, and IJS have nothing to disclose.
: The London Queen Square Ethics committee approved the study. The study complies with the Declaration of Helsinki.
: All participants provided written informed consent at enrollment including consent to publication.